Does LANADELUMAB Cause Poor venous access? 45 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 45 reports of Poor venous access have been filed in association with LANADELUMAB (TAKHZYRO). This represents 2.2% of all adverse event reports for LANADELUMAB.
45
Reports of Poor venous access with LANADELUMAB
2.2%
of all LANADELUMAB reports
1
Deaths
24
Hospitalizations
How Dangerous Is Poor venous access From LANADELUMAB?
Of the 45 reports, 1 (2.2%) resulted in death, 24 (53.3%) required hospitalization, and 1 (2.2%) were considered life-threatening.
Is Poor venous access Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for LANADELUMAB. However, 45 reports have been filed with the FAERS database.
What Other Side Effects Does LANADELUMAB Cause?
Hereditary angioedema (1,343)
Product dose omission issue (555)
Weight decreased (361)
Weight increased (353)
Inappropriate schedule of product administration (318)
Product use issue (229)
Covid-19 (225)
Injection site pain (201)
Insurance issue (172)
Drug ineffective (142)
What Other Drugs Cause Poor venous access?
VEDOLIZUMAB (1,043)
INFLIXIMAB (917)
INFLIXIMAB-DYYB (782)
ECULIZUMAB (555)
HUMAN IMMUNOGLOBULIN G (504)
NATALIZUMAB (422)
RITUXIMAB (299)
TOCILIZUMAB (287)
METHOTREXATE (257)
ABATACEPT (249)
Which LANADELUMAB Alternatives Have Lower Poor venous access Risk?
LANADELUMAB vs LANADELUMAB-FLYO
LANADELUMAB vs LANREOTIDE
LANADELUMAB vs LANSOPRAZOLE
LANADELUMAB vs LANTHANUM
LANADELUMAB vs LANTUS